The global Klinefelter Syndrome Therapeutics Market is expected to surge at a CAGR of 5% from 2023 to 2033, expected to reach a valuation of US$ 1.85 Billion, up from US$ 1.14 Billion in 2023, concludes a recently published Future Market Insights report. Because the disease is difficult to diagnose due to unidentifiable symptoms and indicators, the government, in collaboration with various healthcare organizations such as the FDA and the NIH, is raising awareness about it.
Incentives for all types of health check-ups are also likely to contribute to market growth in the coming years. Men’s fertility disorders have increased dramatically in recent years, which will primarily stimulate the market. Clinical symptoms will appear in men of all ages. This disease is most common in newborn males. Klinefelter syndrome affects one out of every 500 to 1,000 newborn males, based on the National Institute of Health (NIH).
Europe is expected to be the second-fastest-growing region in the industry. The rising prevalence of the disease has enhanced research financing, and health organizations such as the National Institutes of Health (NIH) are focusing on raising awareness about the syndrome, which is cruising market growth.
Request a Sample of this Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16407
North America is expected to dominate the market due to the region’s large number of testosterone drugmakers, as well as increased awareness among the region’s population. In addition, a large number of treatment centers for this ailment will increase market share over the forecast period.
Key Takeaways from the Market Study
- From 2018-2022, a CAGR of 4% was registered for the Klinefelter syndrome therapeutics market
- By therapeutics, testosterone replacement therapy to experience maximum uptake, growing at a 3.1% CAGR
- Hospital pharmacies to remain primary POC for availing Klinefelter syndrome therapeutics drugs, growing at a 4.6% CAGR
- North America to emerge as the kingpin, registering a market share worth 38%
- Europe to be the 2nd largest market, expected to accumulate a 34% revenue share
- Asia Pacific to show significant growth, registering a CAGR of 5.1% until 2033
“With rising instances of male infertility, the need for seeking therapy and diagnostics to detect presence of Klinefelter syndrome is increasing at a fast pace. Treatment providers are therefore endowed with an opportunity to introduce more robust approaches, generating many opportunities,” remarks an FMI analyst.
Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-16407
Key Market Players
Key players in the Klinefeltr Syndrome Therapeutics market are Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co., Ltd, Pfizer Inc, AstraZeneca, AbbVie, Inc, Bausch Health Companies Inc, Bristol Myers Squibb Company, GSK Plc, Novartis AG, Viatris.
- Takeda Pharmaceutical Company Limited and Seagen Inc. announced that data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination would be conveyed verbally at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO).
- In 2021, Pfizer Inc. launched Testosterone Cypionate Injection as a replacement therapy for males suffering from exogenously low testosterone or absence.
Key Segments Profiled in the Klinefelter Syndrome Therapeutics Industry Report
By Therapeutics:
- Testosterone Replacement Therapy
- Fertility Treatment
- Surgeries
- Hormone Treatment
- Others
Request for Customization: https://www.futuremarketinsights.com/customization-available/rep-gb-16407
By Application:
- Hospitals
- Specialty Clinics
- Others
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
